Purified recombinant murine granulocyte/ macrophage colony-stimulating factor (GM-CSF) was labeled with "2'I and used to examine the GM-CSF receptor on unfractionated normal murine bone marrow cells, caseininduced peritoneal exudate cells, and highly purified murine granulocyte/macrophage progenitor cells (CFU-GM). CFU-GM were isolated from cyclophosphamide-treated mice by Ficoll-Hypaque density centrifugation followed by counterfiow centrifugal elutriation. The resulting population had a cloning efficiency of 62-99% in cultures containing conditioned medium from pokeweed mitogen-stimulated spleen cells and 55-86% in the presence of a plateau concentration of purified recombinant murine GM-CSF. Equilibrium binding studies with '2SI-labeled GM-CSF showed that normal bone marrow cells, casein-induced peritoneal exudate cells, and purified CFU-GM had a single class of high-affmity receptor with an approximate Ka of 108-109 M -'. CFU-GM expressed an
average of 3783 ± 4 receptors per cell; normal bone marrow cells, 1518 ± 242 receptors per cell; and peritoneal exudate cells, 2025 ± 216 receptors per cell. Affinity crosslinking studies demonstrated that 125I-labeled GM-CSF bound specifically to two species of Mr 180,000 and 70,000 on CFU-GM, normal bone marrow cells, and peritoneal exudate cells. The Mr 70,000 species is thought to be a proteolytic fragment of the intact Mr 180,000 receptor. The present studies indicate that the GM-CSF receptor expressed on CFU-GM and mature myeloid cells are structurally similar. In addition, the number of GM-CSF receptors on CFU-GM is twice the average number of receptors on casein-induced mature myeloid cells, suggesting that receptor number may decrease as CFU-GM mature.
Granulocyte/macrophage colony-stimulating factor (GM-CSF) is one of a group of functionally related glycoprotein hormones (1, 2) that affect myelopoiesis in vitro (1, 2) and in vivo (1) (2) (3) (4) . GM-CSF was originally identified by its ability to promote the proliferation and differentiation of granulocyte/ macrophage progenitor cells (CFU-GM) in semisolid cultures of hematopoietic cells (5) ; however, it is now apparent that this hormone influences the functional capacity of mature myeloid cells as well (1, 2) . Murine CFU-GM have recently been purified to near homogeneity (6) (up to 99% colony-or cluster-forming cells). CFU-GM isolated by this procedure appear to be functionally normal with respect to their pattern of differentiation in response to colonystimulating factors (6) . The availability of purified CFU-GM will allow the mechanism of action of GM-CSF on CFU-GM to be examined and compared with the mechanism of action on their mature progeny.
GM-CSF-mediated cellular responses appear to be initiated by binding of the hormone to specific cell surface receptors, which have been demonstrated on murine (7) and human (8, 9 ) neutrophils, continuous cell lines (7) (8) (9) (10) (11) , and hematopoietic growth factor-dependent cell lines (7) . Cell lines thought to be at or near the differentiation stage of normal CFU-GM have been studied for GM-CSF receptor expression and the data have been extrapolated to their normal counterparts, but these studies (7) (8) (9) (10) (11) need to be interpreted with caution. Continuous cell lines, unlike normal CFU-GM (12) , do not require the presence of GM-CSF for survival or proliferation, and factor-dependent cell lines do not, as do CFU-GM, differentiate in response to GM-CSF stimulation (13) .
In the present studies, the GM-CSF receptor on highly purified (62-99% pure) murine CFU-GM was examined directly in equilibrium binding studies. Normal bone marrow cells were also studied to provide data on a heterogeneous myeloid cell population containing proliferative and nonproliferative cells and to allow comparisons with previous studies using recombinant (10) and natural (7) GM-CSF preparations. Casein-induced peritoneal exudate cells, which are predominantly granulocytes (14) , served as a mature myeloid cell preparation. Affinity crosslinking studies were conducted with purified CFU-GM, normal bone marrow cells, and mature myelomonocytic peritoneal exudate cells, to compare the molecular structures of the GM-CSF receptor on immature and mature cells of these lineages. The data demonstrate that the number of GM-CSF receptors on CFU-GM is -2-fold higher than the number observed on casein-induced mature neutrophils and monocytes, but both the affinity constant (Ka) and the molecular structure of the receptor are similar on mature and immature cells. We suggest that the pleiotropic responses to GM-CSF stimulation cannot be explained by a gross difference in receptor structure at different differentiation stages. In addition, it appears that the molecular structure of the GM-CSF receptor on some continuous murine cell lines (7, 10, 11) is different from that expressed on primary murine cells (CFU-GM, normal bone marrow cells, or peritoneal exudate cells).
MATERIALS AND METHODS Animals. Female (C57BL/6J x DBA/2)F1 (BDF1) mice, 4-6 weeks old, were purchased from Cumberland View Farms (Clinton, TN).
Abbreviations: GM-CSF, granulocyte/macrophage colony-stimulating factor; 125I-GM-CSF, I25l-labeled GM-CSF; CFU-GM, granulocyte/macrophage precursor cell(s) (colony-forming unit, granulocyte/macrophage); PWMSCM, conditioned medium from pokeweed mitogen-stimulated spleen cells.
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Proc. Natl. Acad. Sci. USA 85 (1988) Cell-Collection Procedures. The method for the purification of murine CFU-GM has been reported (6 (14) . Two injections were given 15 hr apart, and 3 hr after the second injection, peritoneal cells were harvested as described for resident peritoneal cells.
Purification and Iodination of Recombinant Murine GM-CSF. Recombinant murine GM-CSF was prepared in a yeast expression system and purified to homogeneity by reversedphase high-performance liquid chromatography (15) . GM-CSF concentration was determined by radioimmunoassay and biological activity was measured in a mouse bone marrow proliferation assay (16) . lodination of murine recombinant GM-CSF was done with the Enzymobead radioiodination reagent (Bio-Rad) as described previously (10) . 1251. labeled GM-CSF preparations (125I-GM-CSF) lacked high molecular weight aggregates based upon analysis by Sephadex G-75 (Pharmacia) fractionation and retained >50%o biological activity. Studies examining inhibition of 125I-GM-CSF binding to the GM-CSF receptor by unlabeled GM-CSF showed that radiolabeling produces no loss in affinity of the hormone for the receptor (10) . The specific activities of GM-CSF preparations used in these studies were 1.6-1. '"I-GM-CSF Binding Assays. Binding assays were performed as described (10), using a phthalate oil procedure for separating cell-bound and free radioactivity (17) . In brief, 2-10 x 106 normal bone marrow cells, or 3.0-3.4 x i05 FR-28 cells, were suspended in 150 ,ul of binding medium (RPMI 1640 with 2% bovine serum albumin, 20 mM Hepes, and 0.2% sodium azide, pH 7.2) in microcentrifuge tubes. Kinetic experiments previously demonstrated that incubation for 30 min at 37°C was optimal to achieve binding equilibrium (10) . Two 70-,ul aliquots from each tube were removed, and each aliquot was layered atop 200,ul of a mixture of 1.5 parts dibutyl phthalate (Sigma) and 1 part bis(2-ethylhexyl) phthalate (Aldrich) precooled to 4TC. Samples were centrifuged at 13,000 x g for 2 min. Cell-bound (cell pellet) and free (phthalate oil mixture) 125I-GM-CSF was quantitated with a Beckman gamma counter. Nonspecific 125I-GM-CSF binding was determined in the presence of a 42-fold molar excess of unlabeled purified recombinant murine GM-CSF. Sodium azide was included in all binding assays to retard internalization and degradation of the labeled ligand (10) . Binding data were analyzed by the method of Scatchard (18) .
The ligand specificity of the GM-CSF receptor was determined by performing binding assays as described above in the presence of various hematopoietic and nonhematopoietic factors. The following unlabeled factors were used: (i) purified recombinant murine GM-CSF, (ii) purified recombinant human GM-CSF (Immunex, Seattle, WA), (iii) purified murine L-cell colony-stimulating factor 1 [CSF-1 (macrophage CSF), provided by R. K. Shadduck, Pittsburgh; ref. 10 ,uM pepstatin, 10 ,uM leupeptin, 2 mM o-phenanthroline, and 2 mM ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA) (all protease inhibitors were from Sigma). After a 30-min incubation at room temperature, the tubes were centrifuged at 13,000 x g for 10 min. The supernatants were retained, dried under reduced pressure, suspended in 60 p1 of sample buffer (0.06 M Tris HCI, pH 6.8/2% NaDodSO4/ 10% glycerol) containing 2% 2-mercaptoethanol (Sigma), and boiled for 3 min. NaDodSO4/Polyacrylamide Gel Electrophoresis. Samples were electrophoresed in 5-15% linear gradient gels according to the discontinuous system of Laemmli (19) . Gels were stained with Coomassie blue (0.25% in 40% methanol/10% acetic acid) and destained in 40% methanol/10%o acetic acid. Dried gels were exposed to Kodak X-Omat AR film (Kodak) at -700C.
Assay for CFU-GM. FR-28 cells were plated in soft agarose (0.4% final concentration; FMC, Rockland, ME) cultures containing 100 cells, 20%o FBS, and supplemented McCoy's SA medium (4) . Agarose allows for the detection of a greater percentage of CFU-GM than typical agar cultures (6) . CFU-GM were stimulated with plateau concentrations of pokeweed mitogen-stimulated spleen cell conditioned medium (PWMSCM) or purified recombinant murine GM-CSF (4, 20) . Colonies (>50 cells) and clusters (3- expressed as a percentage of the control. The data demonstrate that, with both normal bone marrow and FR-28 cells, only unlabeled recombinant murine GM-CSF could compete effectively for binding with murine 1251I-GM-CSF (Table 2) .
Receptor-Ligand Crosslinking Studies. The molecular structure of the GM-CSF receptor was investigated by affinity crosslinking experiments. The molecular weight of the receptor protein(s) was determined by subtracting the molecular weight of the ligand (Mr 21,000) from the molecular weight of the crosslinked receptor-ligand complex observed on autoradiograms of NaDodSO4/polyacrylamide gels. As noted previously (10) , the GM-CSF receptor on normal bone marrow cells is extremely protease-sensitive and was degraded completely to a form with approximate Mr 70,000 in the absence of protease inhibitors (Fig. LA, lane 5) Fig. 1 A-C, respectively) . Crosslinking was also performed on casein-induced peritoneal cells and gave results identical to those seen with resident peritoneal cells (data not shown). 125I-GM-CSF binding to the receptor was inhibited by a 40-to 100-fold molar excess of unlabeled GM-CSF (Fig. 1, lanes 3 Normal bone marrow cells (NBM, 2 x 106) and purified bone marrow CFU-GM (FR-28, 3 .4 x 105) were suspended in binding medium to which was added 1251-GM-CSF (7. CSF to cell lines and normal bone marrow cells (10) and for the predominant receptor species for purified natural GM-CSF observed on normal bone marrow cells and neutrophilic granulocytes (7) . Recent studies with recombinant human GM-CSF have demonstrated a single class of receptor on cell lines and polymorphonuclear leukocytes (8, 9) , with a Ka of 109-101o M- 1. Molecular heterogeneity of the GM-CSF receptor has been proposed as a possible explanation for the diversity of cellular responses associated with this hormone (10) . The structure of the GM-CSF receptor on CFU-GM, normal bone marrow cells, and peritoneal cells was compared by affinity-crosslinking studies to determine whether receptor structure was the same on mature and immature myeloid cells. The data demonstrated that '25I-GM-CSF was specifically bound to two molecular weight species of cell surface protein, one of Mr 180,000 and one of Mr 70,000. CFU-GM, normal bone marrow cells, and peritoneal cells showed no demonstrable difference in the structure of the receptor as determined by this method, illustrating that the actions of GM-CSF are mediated through a similar if not identical structure on mature and immature cell types. It should be noted that a number of murine cell lines have cell surface GM-CSF receptors with a molecular size quite different from that observed for the receptor on normal bone marrow cells, CFU-GM, or peritoneal cells (10) . This supports our earlier contention that cell-line data may not provide an accurate representation of the GM-CSF receptor on primary cells. We also propose that the Mr 70,000 band seen when crosslinked ligand-receptor complexes are analyzed is a proteolytic cleavage fragment of the higher molecular weight species. This proposal is based on the observation that when normal bone marrow cells were treated with the crosslinking agent and then solubilized in the absence of protease inhibitors, only the Mr 70,000 species was seen (Fig. 2A, lane 5) . It has been suggested (11) that the high molecular weight species (Mr 180,000) may represent a receptor-associated protein or complex because of the concentration of crosslinker (disuccinimidyl tartrate) used in previous experiments (10) . We believe that this is not the case, since crosslinking done with normal bone marrow cells in the absence of protease inhibitors revealed only the Mr 70,000 species. It is unlikely that our results are due to a concentration dependent crosslinking of labeled ligand to a receptor-associated protein, because the concentration of crosslinking agent was the same in experiments conducted with and without protease inhibitors. In addition, previous studies with increasing concentrations of crosslinker (up to 2 mg/ml) did not influence the intensity of the higher molecular weight crosslinked band (10), as would be expected if the Mr 180,000 band was an artifact associated with the concentration of crosslinker. This suggests that the receptor for recombinant murine GM-CSF on primary cells has a molecular weight of 4180,000. However, since no experiments revealed only the Mr 180,000 species, we cannot rule out the possibility that both molecular weight species represent intact GM-CSF receptors.
The average number of GM-CSF receptors is higher than expected on murine CFU-GM based upon previous studies using cell lines (7, 10, 11) . Not all of the CFU-GM detectable in FR-28 with crude PWMSCM respond in vitro to GM-CSF (19) . We do not know whether CFU-GM that do not form colonies in response to plateau levels of GM-CSF express the GM-CSF receptor, but if not, this would contribute to an underestimation of the GM-CSF receptor number, since the values obtained represent an average for all cells in this fraction. The average number of GM-CSF receptors on casein-induced peritoneal exudate cells, composed primarily of granulocytes (14) , was approximately half the number observed on FR-28 CFU-GM. This suggests that GM-CSF receptor number decreases during differentiation from CFU-GM to mature myeloid cell; however, the effect of in vivo cytokine exposure on GM-CSF receptor number after casein-induction of the peritoneal exudate is unclear. The number of GM-CSF receptors per peritoneal exudate cell in the present studies was higher than that reported in previous studies with purified natural 125I-GM-CSF (14 Proc. Nad. Acad Sci. USA 85 (1988) studies, but a higher concentration of sodium azide was used in the present studies. This higher azide concentration makes it unlikely that an enhanced rate of receptor turnover with subsequent binding of additional 125I-GM-CSF to newly deployed receptors during the 30-min binding assay could account for the higher receptor number seen in these studies. Previous studies (14) , performed with normal bone marrow cells and 1/10th as much sodium azide as was used in the current experiments, suggested that receptor cycling, leading to expression of additional GM-CSF receptors induced by binding of the ligand, was effectively inhibited by sodium azide. This is further supported by studies showing that no intracellular pool of GM-CSF receptors can be detected in WEHI-3B cells (responsive to GM-CSF) and that redeployment of receptors after internalization and release of the ligand at 370C requires greater than 30 min to become apparent (11) . Thus, the higher number of GM-CSF receptors in the present studies may be due to the use of a slightly different target-cell population or to differences in the iodinated GM-CSF preparations; for instance, glycosylation has recently been shown to influence the biological activity of this hormone in vitro (21) .
It is important, in light of clinical trials with GM-CSF and other colony-stimulating factors, that the mechanism of action of these molecules be understood. By knowing how mature and immature myeloid cells respond to exposure to GM-CSF, therapeutic intervention with these molecules may be targeted more directly to the cell type desired. In this study we examined the GM-CSF receptor on mature and immature cells of the myeloid pathway and found that no gross structural change in the receptor occurs during differentiation. The similarity (in Ka and structure) between the receptors for GM-CSF on mature and immature myeloid cells suggests that the pleiotropic responses to GM-CSF seen at various stages of differentiation are probably due to postreceptor phenomena.
